Dendritic cell-tumor cell hybrid vaccination for metastatic cancer

被引:63
作者
Barbuto, JAM
Ensina, LFC
Neves, AR
Bergami-Santos, PC
Leite, KRM
Marques, R
Costa, F
Martins, SC
Camara-Lopes, LH
Buzaid, AC
机构
[1] ICB USP, Dept Imunol, BR-05508000 Sao Paulo, Brazil
[2] Hosp Sirio Libanes, BR-01308050 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
dendritic cells; hybrid cell vaccination; melanoma; renal cell carcinoma;
D O I
10.1007/s00262-004-0551-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells are the most potent antigen-presenting cells, and the possibility of their use for cancer vaccination has renewed the interest in this therapeutic modality. Nevertheless, the ideal immunization protocol with these cells has not been described yet. In this paper we describe the preliminary results of a protocol using autologous tumor and allogeneic dendritic hybrid cell vaccination every 6 weeks, for metastatic melanoma and renal cell carcinoma (RCC) patients. Thirty-five patients were enrolled between March 2001 and March 2003. Though all patients included presented with large tumor burdens and progressive diseases, 71% of them experienced stability after vaccination, with durations up to 19 months. Among RCC patients 3/22 (14%) presented objective responses. The median time to progression was 4 months for melanoma and 5.7 months for RCC patients; no significant untoward effects were noted. Furthermore, immune function, as evaluated by cutaneous delayed-type hypersensitivity reactions to recall antigens and by peripheral blood proliferative responses to tumor-specific and nonspecific stimuli, presented a clear tendency to recover in vaccinated patients. These data indicate that dendritic cell-tumor cell hybrid vaccination affects the natural history of advanced cancer and provide support for its study in less advanced patients, who should, more likely, benefit even more from this approach.
引用
收藏
页码:1111 / 1118
页数:8
相关论文
共 35 条
[1]  
Avigan David, 2003, Clin Breast Cancer, V3 Suppl 4, pS158, DOI 10.3816/CBC.2003.s.006
[2]  
Banchereau J, 2001, CANCER RES, V61, P6451
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]  
Chang AE, 2002, CLIN CANCER RES, V8, P1021
[6]   Altered maturation of peripheral blood dendritic cells in patients with breast cancer [J].
Della Bella, S ;
Gennaro, M ;
Vaccari, M ;
Ferraris, C ;
Nicola, S ;
Riva, A ;
Clerici, M ;
Greco, M ;
Villa, ML .
BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1463-1472
[7]  
ELFENBEIN GJ, 1974, J IMMUNOL, V112, P2166
[8]  
Fallarino F, 1999, INT J CANCER, V80, P324, DOI 10.1002/(SICI)1097-0215(19990118)80:2<324::AID-IJC25>3.0.CO
[9]  
2-D
[10]   Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor [J].
Ferrari, S ;
Rovati, B ;
Porta, C ;
Alessandrino, PE ;
Bertotini, A ;
Collovà, E ;
Riccardi, A ;
Danova, M .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (06) :359-366